WILMINGTON, Mass., March 25, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detector (ETD) has received regulatory approval from the German Federal Ministry of the Interior for aviation security applications at German airports. The QS-B220 fulfills specifications set by the German Federal Police. With the German Federal Ministry of the Interior approval, the QS-B220 may now be deployed at all non-passenger airport checkpoints for screening of deliveries, food service, and other airport service functions.
Testing and evaluation was conducted at the German National Test Center for the Evaluation of Explosives Detection Systems, established by the German Federal Police, in conjunction with the Fraunhofer Institute for Chemical Technology (ICT). The realistic testing environment provided by the Center is essential for security services and end users such as airport operators to obtain reliable performance data and ensure a uniform security standard throughout Europe.
"This testing was performed at the request of an airport in Germany that plans to use the QS-B220 to speed up their inspection process at apron checkpoints. Successful completion of the approval process opens up opportunities at airports through the region," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.
"This product approval, which was performed using the latest test protocols and obtained through a key testing facility, further solidifies Implant Sciences' role as the new standard of trace detection. Our plan is to continue to expand our range of certifications, which includes the U.S., France, China, and now Germany. We believe this will allow us to increase sales volumes and revenues for our Company," added Implant Sciences' President and CEO, Glenn D. Bolduc.
On February 4, 2013, the EU implemented an amendment to Regulation (EU) No 185/2010, in regards to the screening of passengers and persons other than passengers by Explosives Trace Detection (ETD) equipment in combination with Handheld Metal Detection (HHMD) equipment, which stated that "trials have demonstrated the effectiveness of the combined use of ETD and HHMD. Moreover, the use of ETD and HHMD may facilitate the screening process and be experienced to be a less intrusive means of screening than a hand search, thus constituting an improvement in the experience of persons screened."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal(TM) internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. As of January 2013, the Company is only the third ETD manufacturer, and the first American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation